Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

NCT01191372 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01191372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1
Overall status
Terminated
Start date
September 15, 2010
Completion date
December 28, 2011
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia